GHRP-2 vs Sermorelin
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Growth Hormone Releasing Peptide 2, Pralmorelin
GHRP-2 (generic name pralmorelin) is a synthetic hexapeptide growth hormone secretagogue and a second-generation cousin of GHRP-6. It prompts the pituitary to release growth hormone and is the one peptide in this family with an actual regulatory approval: it is licensed in Japan as a diagnostic agent for growth hormone deficiency. Outside that narrow diagnostic use it has no approval and is sold elsewhere only as a research compound.
Also: Geref, GRF 1-29
Sermorelin is a 29-amino-acid fragment of human growth hormone-releasing hormone (GHRH), and it is the shortest piece of GHRH that still works fully. It asks the pituitary to make and release its own growth hormone rather than injecting GH itself. It was once an FDA-approved drug for diagnosing and treating growth hormone deficiency in children, but the manufacturer pulled it from the market in 2008, so today it is available mainly through compounding pharmacies for off-label use.
Key Comparison Insights
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
- GHRP-2 has stronger research evidence (Human Trials) compared to Sermorelin (Animal Studies).
Detailed Comparison
| Attribute | GHRP-2 | Sermorelin |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Like GHRP-6, GHRP-2 is an agonist at the ghrelin / growth hormone secretagogue receptor (GHS-R1a). Binding that receptor in the pituitary and hypothalamus drives a pulse of growth hormone release. It was designed to be more potent and somewhat cleaner than GHRP-6, with a milder effect on appetite, though it still acts on the ghrelin system so it is not free of off-target hormonal effects. Because it works upstream of the pituitary rather than replacing GH directly, the GH release it causes is still subject to the body's own feedback brakes such as somatostatin. | Sermorelin copies the first 29 amino acids of natural GHRH and binds the GHRH receptor on the anterior pituitary, which is the body's normal on-switch for growth hormone production. Activating that receptor tells the pituitary to synthesize and release GH in pulses. A useful safety feature falls out of this design: because the pituitary still answers to its own inhibitory hormone somatostatin, the GH rise stays under negative-feedback control, which makes a true overdose of GH much harder to produce than with injected recombinant GH. |
| Common Dosing | 100-300 mcg 2-3x daily 2-3x daily | 200-500 mcg before bed Once daily, typically before bed |
| Administration | Subcutaneous injection | Subcutaneous injection at bedtime |
| Typical Duration | 8-12 weeks | 3-6 months typical |
| Best Time to Take | Before bed or morning (fasted) | Before bed (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | GHRP-2 has genuine human data behind its diagnostic role. In Japan it reached phase II trials and was approved as pralmorelin (intravenous) to test for growth hormone deficiency, including in children with short stature, making it the only GH secretagogue in this class with any regulatory approval. A published human pharmacology study detected unchanged GHRP-2 and its metabolite AA-3 in the urine of ten male volunteers given the drug intravenously, work driven largely by anti-doping testing because GHRP-2 is banned in sport. What it does NOT have is solid controlled-trial evidence for the body-composition, anti-aging, or recovery uses it is marketed for online. So the honest picture is a real, approved diagnostic tool in one country, with everything beyond that being off-label or unproven research use. | Sermorelin has a real clinical pedigree, unlike many gray-market peptides. The FDA approved it in 1990 as a diagnostic for GH deficiency and in 1997 for treating idiopathic GH deficiency in children with growth failure, after studies showed about six months of daily injections increased GH release and growth velocity. Published work found intravenous sermorelin is a relatively specific test for GH deficiency with few false positives, and once-daily subcutaneous dosing promoted growth in some GH-deficient prepubertal children. Where the evidence gets thin is the popular adult anti-aging use: a 2006 editorial argued sermorelin is a smarter way to address age-related GH decline than recombinant GH, but it openly conceded that few long-term clinical studies exist. The drug was discontinued commercially in 2008 for business reasons, not safety, so current adult use rests on compounded product and limited modern trial data. |
Frequently Asked Questions: GHRP-2 vs Sermorelin
What is the difference between GHRP-2 and Sermorelin?
GHRP-2 is a growth hormone peptide that ghrp-2 (generic name pralmorelin) is a synthetic hexapeptide growth hormone secretagogue and a second-generation cousin of ghrp-6. it prompts the pituitary to release growth hormone and is the one peptide in this family with an actual regulatory approval: it is licensed in japan as a diagnostic agent for growth hormone deficiency. outside that narrow diagnostic use it has no approval and is sold elsewhere only as a research compound. Sermorelin is a growth hormone peptide that sermorelin is a 29-amino-acid fragment of human growth hormone-releasing hormone (ghrh), and it is the shortest piece of ghrh that still works fully. it asks the pituitary to make and release its own growth hormone rather than injecting gh itself. it was once an fda-approved drug for diagnosing and treating growth hormone deficiency in children, but the manufacturer pulled it from the market in 2008, so today it is available mainly through compounding pharmacies for off-label use. The main differences lie in their mechanisms of action and clinical applications.
Which is better, GHRP-2 or Sermorelin?
Neither is universally "better" - the choice depends on your specific goals. GHRP-2 is typically used for growth hormone purposes, while Sermorelin is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can GHRP-2 and Sermorelin be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using GHRP-2 and Sermorelin together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.